Drug Discovery · Cambridge, MA · Founded 2019 · In IPO Registration
Developer of prophylactic therapeutics designed for bleeding and thrombosis disorders. Hemab Therapeutics Holdings is based in Cambridge, MA and was founded in 2019. It is valued at about $387 million as of Oct 2026, set by institutional fund marks. It has raised $355 million across 2 recorded rounds; the latest was a $157 million Series C in Oct 2025.
PMV mark · valuation
$386.9M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$355.1M
Last round
Later Stage VC (Series C)
Oct 2025
Cap table — not yet on record
Hemab Therapeutics Holdings's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Frequently asked about Hemab Therapeutics Holdings
Where does Hemab Therapeutics Holdings's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Hemab Therapeutics Holdings's 2 recorded funding rounds.
